Showing posts with label MUTATIONS. Show all posts
Showing posts with label MUTATIONS. Show all posts

Saturday, August 5, 2017

Mutations In A Sodium Channel Reponsible For Painful Neuropathy


Not exactly a catchy title to catch your eye over the breakfast cereal but nevertheless, today's post from painresearchforum.org (see link below) is a fascinating look at how neuropathy may look under the microscope. Basically, research has found that there may be genetic reasons for mutations in one of the three sodium channels in nerves and nerve cells that normally control how excitable pain-sensing nociceptors might be. These mutations may stop that control and allow the pain signals to get out of hand. Having discovered that genetic influences may be at work, it's thought that drugs can be targeted more specifically to quieten that excitement down. It sounds complex and technical and is but that should never stop us trying to understand what's going on in our bodies that cause such uncomfortable symptoms. You can probably get the gist of what they're talking about here.

Third Sodium Channel Implicated in Painful Small-Fiber Neuropathy
Mutations in Nav1.9 render pain neurons hyperexcitable 

by Stephani Sutherland on 16 May 2014


Three voltage-gated sodium channels—Nav1.7, 1.8, and 1.9—all participate in tuning the excitability of pain-sensing nociceptors. Genetic changes that alter the function of two of the channels, 1.7 and 1.8, and boost nociceptor activity have been found in patients with painful small-fiber neuropathy (SFN), a common condition with often mysterious origins. Now, an international consortium of researchers has rounded out the Nav triad by identifying gain-of-function mutations in Nav1.9 in some cases of painful SFN. The new findings reveal a previously unsuspected genetic cause for painful peripheral neuropathy and further validate Nav1.9 as a potential target for new drugs aimed at quieting pain neurons. The study, a collaborative effort between US and European researchers, was published April 27 in Brain.

In a commentary accompanying the paper, David Bennett of the University of Oxford, UK, who was not involved in the current study, wrote that the researchers “present the first evidence for a causative role of missense mutations in Nav1.9 in painful neuropathy.” As a result, he wrote, “Mutations in Nav1.7, 1.8, and 1.9 have now all been associated with painful neuropathy as a consequence of dorsal root ganglion [DRG] cell hyperexcitability and as such are targets for the development of novel analgesics.”

For the study, neurologists Ingemar Merkies and Catharina Faber at the University Medical Centre, Maastricht, the Netherlands, and Giuseppe Lauria at IRCCS Foundation, "Carlo Besta" Neurological Institute, Milan, Italy, carefully characterized a cohort of 393 patients with pure or predominantly small-fiber neuropathy. They previously identified mutations in SCN9A and SCN10A, encoding Nav1.7 and Nav1.8, respectively, in some of the cohort (see PRF related news story on Faber et al., 2012; also Faber et al., 2012). The team now reports eight variants in SCN11A—the gene that encodes Nav1.9—in 12 of the remaining 345 subjects. The variants were all heterozygous, and seven caused amino acid sequence changes in the Nav1.9 protein. None of the eight variants were found in 694 chromosomes from healthy control subjects.

Stephen Waxman, Sulayman Dib-Hajj, and their team at Yale University School of Medicine, New Haven, and the Veterans Affairs Medical Center, West Haven, both in Connecticut, US, followed up on the genetic work with what Bennett described as “a detailed and elegant functional analysis” of two of the missense mutations. Each mutation was found in two patients; one resulted in a leucine-to-proline change at position 1158 (L1158P), and the other caused an isoleucine-to-threonine swap at position 381 (I381T).

First authors Jianying Huang, Chongyang Han, Mark Estacion, and Dymtro Vasylyev—whom Dib-Hajj called “four highly specialized and talented electrophysiologists”—carried out the analysis. Using patch-clamp recording techniques on isolated mouse dorsal root ganglia (DRG) neurons made to express only the human channels, the researchers determined that both mutations altered the channels’ gating properties. Importantly, DRG neurons expressing mutant channels alongside the rodent channel were significantly more prone to fire both spontaneous and evoked action potentials than those expressing wild-type human channels.

The neuronal excitability experiments could be misleading due to high expression levels of the mutant channels and/or the presence of the rodent channel. To address that problem, the authors used a sophisticated dynamic clamp technique, where they "injected” currents into mouse DRG neurons that lacked their own Nav1.9 to mimic physiological levels of wild-type human channels or a 50/50 combination of wild-type and mutant channels. The results confirmed that currents generated by the I381T mutant channels were capable of causing changes in cell excitability similar to those measured in the expression experiments, suggesting that the effects were “not an aberrant effect of overexpression of a mutant protein,” Waxman told PRF.

Recently, gain-of-function mutations in Nav1.9 were found in two families with a rare inherited episodic pain condition (see PRF related news story on Zhang et al., 2013), and the new work links Nav1.9 mutations to a more common condition, painful SFN. However, a different gain-of-function mutation has also been found in two people with insensitivity to pain (see PRF related news story on Leipold et al., 2013). In that study, the authors postulated that a constant, slight depolarization of the membrane potential induced by the Nav1.9 mutant would inactivate sodium channels and render cells unexcitable. Based on their electrophysiological studies, Waxman said his group found no evidence that a depolarized resting potential in DRG neurons reduced their excitability, leaving open the question of how the mutation described by Leipold et al. might lead to pain insensitivity.

Neurotoxic mutants?

SFN pain symptoms vary from patient to patient, but usually include burning pain and tingling that originates in the hands or feet, along with other unpleasant sensations. About half of SFN cases can be traced to nerve damage due to diabetes, cancer, toxins, or other insults. But for the rest of patients, SFN has unexplained origins. Could the newly identified Nav1.9 mutations cause SFN in some? Waxman told PRF, “The mutations unequivocally cause DRG neuron hyperexcitability, which is a major contributor to pain.”

SFN also features damage to small-diameter nerve endings, detectable with a skin biopsy. Waxman suggests that in addition to pain, overactivity of Nav1.9 or other mutant sodium channels could contribute to this unexplained neurodegeneration and that quieting the channels might curtail the damage. Bennett, too, suggested in his editorial that drugs aimed at quieting Nav1.9, besides acting as analgesics, “may have the added advantage of also being disease modifying.”

Together with last year's findings in rare disorders, the finding of Nav1.9 mutations in SFN breathes new life into that channel as a potential therapeutic target. Pharmaceutical companies are actively pursuing Nav1.7 and Nav1.8 as analgesic drug targets, but industry has thus far shied away from Nav1.9 because of the lack of a connection to human pain and also because of technical difficulties associated with studying the channel. Dib-Hajj told PRF, “Until now, people did not really know what to make of this channel.” In light of the new findings, though, Dib-Hajj said, “Now they can’t ignore it.”

Of course, efforts to develop a Nav1.9 blocker would be aimed not only at the few patients with mutations in the channel, but also at a much broader population suffering from SFN or even neuropathic pain more generally. “It is clear to us that Nav1.9 behaves as a threshold channel, that it is important to setting the resting membrane potential of neurons, and it controls excitability … in the case of the wild-type channel, too, not just mutants. So if you can attenuate Nav1.9 [activity], chances are you will ameliorate pain,” said Dib-Hajj. “That is based on biology, not wishful thinking.” Still, when it comes to a Nav1.9-specific blocker, Dib-Hajj said, “We predict that patients would benefit, but the proof will be in the pudding.”

Stephani Sutherland, PhD, is a neuroscientist, yogi, and freelance writer in Southern California.

http://www.painresearchforum.org/news/40751-third-sodium-channel-implicated-painful-small-fiber-neuropathy

Thursday, July 6, 2017

ULTRAVIOLET LIGHT INDUCED MUTATIONS DRIVES MANY SKIN CANCERS




A genetic mutation caused by ultraviolet light is likely the driving force behind millions of human skin cancers, according to researchers at the Stanford University School of Medicine

The mutation occurs in a gene called KNSTRN, which is involved in helping cells divide their DNA equally during cell division.
Genes that cause cancer when mutated are known as oncogenes. Although KNSTRN hasn't been previously implicated as a cause of human cancers, the research suggests it may be one of the most commonly mutated oncogenes in the world.

"This previously unknown oncogene is activated by sunlight and drives the development of cutaneous squamous cell carcinomas," said Paul Khavari, MD, PhD, the Carl J. Herzog Professor in Dermatology in the School of Medicine and chair of the Department of Dermatology. "Our research shows that skin cancers arise differently from other cancers, and that a single mutation can cause genomic catastrophe."
Cutaneous squamous cell carcinoma is the second most common cancer in humans. More than 1 million new cases are diagnosed globally each year. The researchers found that a particular region of KNSTRN is mutated in about 20 percent of cutaneous squamous cell carcinomas and in about 5 percent of melanomas.

A paper describing the research will be published online Sept. 7 in Nature Genetics. Khavari, who is also a member of the Stanford Cancer Institute and chief of the dermatology service at the Veterans Affairs Palo Alto Health Care System, is the senior author of the paper. Postdoctoral scholar Carolyn Lee, MD, PhD, is the lead author.

Lee and Khavari made the discovery while investigating the genetic causes of cutaneous squamous cell carcinoma. They compared the DNA sequences of genes from the tumor cells with those of normal skin and looked for mutations that occurred only in the tumors. They found 336 candidate genes for further study, including some familiar culprits. The top two most commonly mutated genes were CDKN2A and TP53, which were already known to be associated with squamous cell carcinoma.
The third most commonly mutated gene, KNSTRN, was a surprise. It encodes a protein that helps to form the kinetochore -- a structure that serves as a kind of handle used to pull pairs of newly replicated chromosomes to either end of the cell during cell division. Sequestering the DNA at either end of the cell allows the cell to split along the middle to form two daughter cells, each with the proper complement of chromosomes.

If the chromosomes don't separate correctly, the daughter cells will have abnormal amounts of DNA. These cells with extra or missing chromosomes are known as aneuploid, and they are often severely dysfunctional. They tend to misread cellular cues and to behave erratically. Aneuploidy is a critical early step toward the development of many types of cancer.

The mutation in the KNSTRN gene was caused by the replacement of a single nucleotide, called a cytosine, with another, called a thymine, within a specific, short stretch of DNA. The swap is indicative of a cell's attempt to repair damage from high-energy ultraviolet rays, such as those found in sunlight.
"Mutations at this UV hotspot are not found in any of the other cancers we investigated," said Khavari. "They occur only in skin cancers."

The researchers found the UV-induced KNSTRN mutation in about 20 percent of actinic keratoses -- a premalignant skin condition that often progresses to squamous cell carcinoma -- but never in 122 samples of normal skin, indicating the mutation is likely to be an early event in the development of squamous cell carcinomas.

Furthermore, overexpression of mutant KNSTRN in laboratory-grown human skin cells disrupted their ability to segregate their DNA during cell division and enhanced the growth of cancer cells in a mouse model of squamous cell carcinoma.

Finally, Lee compared five patient-derived squamous cell carcinomas that had the KNSTRN mutation with five samples that did not have the mutation. Although both sets of cells were aneuploid, those with the mutation had the most severely abnormal genomes.
The identification of a new oncogene will allow researchers to better understand how these types of skin cancers develop. It may also give them clues about how to develop new therapies for the disease. In this case, it also neatly connects the dots between sun exposure and skin cancer.
"Essentially, one ultraviolet-mediated mutation in this region promotes aneuploidy and subsequent tumorigenesis," said Khavari. "It is critical to protect the skin from the sun."